Rapid Reference

  • Nitroglycerin 5 mg p.i. q30min
  • Milrinon 5 mg p.i. q3h
  • iNO 20 ppm ITN, 50 ppm nasal
  • I: Crashing RV (LAE, pHTN, RV-Infarkt), ARDS
  • KI: verschlechtert kardiogenes Lungenödem, NO wirkt antikoagulatorisch
  • WM: Pulmonale Vasodilatation, V/Q-Matching1, Shuntvolumen↓2

Literatur

  • Choobdar FA, Shahhosseini P, Vahedi Z, Khosravi N, Khalesi N, Ghassemzadeh M. Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource-limited settings: A randomized clinical trial. Pediatr Pulmonol. 2023 Jul;58(7):2132-2139.
  • Jorairahmadi S, Javaherforooshzadeh F, Babazadeh M, Gholizadeh B, Bakhtiari N. Comparison of Nebulized Versus Intravenous Milrinone on Reducing Pulmonary Arterial Pressure in Patients with Pulmonary Hypertension Candidate for Open-cardiac Surgery: A Double-Blind Randomized Clinical Trial. Anesth Pain Med. 2022 Jul 21;12(3):e122994.
  • Ghany Hassan AK, A. Sultan SS, Ismail Mostafa WE, El-Komos Samaan PM, F. Saeed AS. Study of the hemodynamic effect of inhaled milrinone versus inhaled nitroglycerin on mechanically ventilated patients with pulmonary hypertension after mitral valve replacement surgeries. J Med Sci Res 2022;5:331-8
  • Patel J, Patel K, Garg P, Patel S. Inhaled versus intravenous milrinone in mitral stenosis with pulmonary hypertension. Asian Cardiovascular and Thoracic Annals. 2021;29(3):170-178
  • Marwali EM, Rayhan M, Roebiono PS. Nitroglycerin inhalation for acute treatment of pulmonary arterial hypertension in children with congenital heart disease. Cardiol Young. 2021 Sep;31(9):1381-1385.
  • Kundra TS, Prabhakar V, Kaur P, Manjunatha N, Gandham R. The Effect of Inhaled Milrinone Versus Inhaled Levosimendan in Pulmonary Hypertension Patients Undergoing Mitral Valve Surgery - A Pilot Randomized Double-Blind Study. J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2123-2129.
  • Denault AY, Bussières JS, Arellano R, Finegan B, Gavra P, Haddad F, Nguyen AQN, Varin F, Fortier A, Levesque S, Shi Y, Elmi-Sarabi M, Tardif JC, Perrault LP, Lambert J. A multicentre randomized-controlled trial of inhaled milrinone in high-risk cardiac surgical patients. Can J Anaesth. 2016 Oct;63(10):1140-1153.
  • Singh R, Choudhury M, Saxena A, Kapoor P, Juneja R, Kiran U. Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension. J Cardiothorac Vasc Anesth. 2010;24(5):797-801.
  • Mandal B, Kapoor PM, Chowdhury U, Kiran U, Choudhury M. Acute hemodynamic effects of inhaled nitroglycerine, intravenous nitroglycerine, and their combination with intravenous dobutamine in patients with secondary pulmonary hypertension. Ann Card Anaesth. 2010 May-Aug;13(2):138-44.
  • Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther. 2009;26(4):462-468.
  • Yurtseven N, Karaca P, Uysal G, et al. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg. 2006;12(5):319-323.
  • Goyal P, Kiran U, Chauhan S, Juneja R, Choudhary M. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth. 2006;97(2):208-214.
  • Lamarche Y, Malo O, Thorin E, Denault A, Carrier M, Roy J, Perrault LP. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005 Jul;130(1):83-92.
  • Nguyen AQ, Denault AY, Théoret Y, Perrault LP, Varin F. Inhaled milrinone in cardiac surgical patients: a pilot randomized controlled trial of jet vs. mesh nebulization. Sci Rep. 2020;10(1):2069.
  • Gavra P, Laflamme M, Denault AY, Théoret Y, Perrault LP, Varin F. Use of nebulized milrinone in cardiac surgery; Comparison of vibrating mesh and simple jet nebulizers. Pulm Pharmacol Ther. 2017;46:20-29.

Footnotes

  1. Inhalative Pulmodilatatoren kommen in gut ventilierten Lungenarealen an und bewirken dort lokal Vasodilatation und vermehrte Perfusion → V/Q-Match, bessere Oxygenierung bei ARDS

  2. PFO/ASD/VSD ist Prädiktor für Ansprechen auf Pulmodilatatoren bei pHTN, TTE Bubble Test